These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 19710553)

  • 1. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
    Kyriakou A; Patsatsi A; Sotiriadis D
    J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-label dermatologic uses of anti-TNF-a therapies.
    Alexis AF; Strober BE
    J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation].
    Levy-Roy A; Porcher R; de Fonclare AL; Morel P; Dupuy A
    Ann Dermatol Venereol; 2009 Apr; 136(4):315-22. PubMed ID: 19361697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
    Karampetsou MP; Liossis SN; Sfikakis PP
    QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological agents in the treatment of psoriasis.
    Tzu J; Krulig E; Cardenas V; Kerdel FA
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of the tumor necrosis factor antagonists.
    Bachmann F; Nast A; Sterry W; Philipp S
    Semin Cutan Med Surg; 2010 Mar; 29(1):35-47. PubMed ID: 20430306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
    Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
    Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab vs. etanercept in psoriasis.
    Downs AM
    Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.
    Bansback N; Sizto S; Sun H; Feldman S; Willian MK; Anis A
    Dermatology; 2009; 219(3):209-18. PubMed ID: 19657180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab treatment in psoriatic arthritis: our experience.
    Rioda WT; Adorni G
    Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
    Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
    JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-TNF alpha in the treatment of psoriatic arthritis].
    Claudepierre P; Wendling D; Cohen JD
    Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
    Fénix-Caballero S; Alegre-del Rey EJ; Castaño-Lara R; Puigventós-Latorre F; Borrero-Rubio JM; López-Vallejo JF
    J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
    Van L; Modi SV; Yang DJ; Hsu S
    Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
    Brunasso AM; Puntoni M; Salvini C; Delfino C; Curcic P; Gulia A; Massone C
    Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer treatment options for patients with moderate-to-severe psoriatic disease.
    Roebuck HL
    Nurse Pract; 2006 Aug; 31(8):5-6,11. PubMed ID: 16966969
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor necrosis factor inhibitors in psoriasis: an update.
    Kerdel FA; Strober BE
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.